James O'COnnell

James O'COnnell

Auto-generated profile, based on publicly available information

James O'COnnell

Early Solutions, UCB Biopharma UK, 208 Bath Road, Slough, SL1 3WE, UK

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
JOJames O’cOnnell
James O’cOnnell
JPJohn Porter
John Porter
BKBoris Kroeplien
Boris Kroeplien
TNTim Norman
Tim Norman
SRStephen Rapecki
Stephen Rapecki
ALAlastair Lawson
Alastair Lawson
Tumour necrosis factor (TNF) is a cytokine belonging to a family of trimeric proteins; it has been shown to be a key mediator in autoimmune diseases such as rheumatoid arthritis and Crohn’s disease. While TNF is the target of several successful biologic drugs, attempts to design small molecule therapies directed to this cytokine have not led to approved products. Here we report the discovery of potent small molecule inhibitors of TNF that stabilise an asymmetrical form of the soluble TNF trimer, compromising signalling and inhibiting the functions of TNF in vitro and in vivo. This discovery paves the way for a class of small molecule drugs capable of modulating TNF function by stabilising a naturally sampled, receptor-incompetent conformation of TNF. Furthermore, this approach may prove to be a more general mechanism for inhibiting protein–protein interactions.

25 January 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
DMDavid McMillan
David McMillan
CMCarlos Martinez-Fleites
Carlos Martinez-Fleites
JPJohn Porter
John Porter
DFDavid Fox
David Fox
RDRachel Davis
Rachel Davis
JOJames O’cOnnell
James O’cOnnell
Tumour necrosis factor (TNF) is a trimeric protein which signals through two membrane receptors, TNFR1 and TNFR2. Previously, we identified small molecules that inhibit human TNF by stabilising a distorted trimer and reduce the number of receptors bound to TNF from three to two. Here we present a biochemical and structural characterisation of the small molecule-stabilised TNF-TNFR1 complex, providing insights into how a distorted TNF trimer can alter signalling function. We demonstrate that the inhibitors reduce the binding affinity of TNF to the third TNFR1 molecule. In support of this, we show by X-ray crystallography that the inhibitor-bound, distorted, TNF trimer forms a complex with a dimer of TNFR1 molecules. This observation, along with data from a solution-based network assembly assay, leads us to suggest a model for TNF signalling based on TNF-TNFR1 clusters, which are disrupted by small molecule inhibitors.

12 January 2013 in BMC Cell Biology
Verified
Journal Article
Open access
PDF file
RYRahul B Yadav
Rahul B Yadav
PBPierre Burgos
Pierre Burgos
APAnthony W Parker
Anthony W Parker
VIValentina Iadevaia
Valentina Iadevaia
CPChristopher Proud
Christopher Proud
Stanley BotchwayStanley Botchway
Stanley Botchway
Background: The mammalian target of rapamycin (mTOR) signalling pathway has a key role in cellular regulation and several diseases. While it is thought that Rheb GTPase regulates mTOR, acting immediately upstream, while raptor is immediately downstream of mTOR, direct interactions have yet to be verified in living cells, furthermore the localisation of Rheb has been reported to have only a cytoplasmic cellular localization. Results: In this study a cytoplasmic as well as a significant sub-cellular nuclear mTOR localization was shown , utilizing green and red fluorescent protein (GFP and DsRed) fusion and highly sensitive single photon counting fluorescence lifetime imaging microscopy (FLIM) of live cells. The interaction of the mTORC1 components Rheb, mTOR and raptor, tagged with EGFP/DsRed was determined using fluorescence energy transfer-FLIM. The excited-state lifetime of EGFP-mTOR of ~2400 ps was reduced by energy transfer to ~2200 ps in the cytoplasm and to 2000 ps in the nucleus when co-expressed with DsRed-Rheb, similar results being obtained for co-expressed EGFP-mTOR and DsRed-raptor. The localization and distribution of mTOR was modified by amino acid withdrawal and re-addition but not by rapamycin. Conclusions: The results illustrate the power of GFP-technology combined with FRET-FLIM imaging in the study of the interaction of signalling components in living cells, here providing evidence for a direct physical interaction between mTOR and Rheb and between mTOR and raptor in living cells for the first time.

25 January 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
DLDaniel J. Lightwood
Daniel J. Lightwood
RMRebecca J. Munro
Rebecca J. Munro
JPJohn Porter
John Porter
DMDavid McMillan
David McMillan
BCBruce Carrington
Bruce Carrington
ALAlastair D. G. Lawson
Alastair D. G. Lawson
We have recently described the development of a series of small-molecule inhibitors of human tumour necrosis factor (TNF) that stabilise an open, asymmetric, signalling-deficient form of the soluble TNF trimer. Here, we describe the generation, characterisation, and utility of a monoclonal antibody that selectively binds with high affinity to the asymmetric TNF trimer–small molecule complex. The antibody helps to define the molecular dynamics of the apo TNF trimer, reveals the mode of action and specificity of the small molecule inhibitors, acts as a chaperone in solving the human TNF–TNFR1 complex crystal structure, and facilitates the measurement of small molecule target occupancy in complex biological samples. We believe this work defines a role for monoclonal antibodies as tools to facilitate the discovery and development of small-molecule inhibitors of protein–protein interactions.

1 March 2023 in Bioanalysis
Verified
Journal Article
Closed access
EHElizabeth S Hickford
Elizabeth S Hickford
JOJames O'COnnell
James O'COnnell
AMAlison Maloney
Alison Maloney
PFPeter Florian
Peter Florian
GJGeoffrey I Johnston
Geoffrey I Johnston
TBTim Bourne
Tim Bourne
Background: An antibody specific to small-molecule inhibitor-bound TNF has enabled the development of target occupancy biomarker assays to support the development of novel treatments for autoimmune...